Transforming Immunotherapy: Kenox Pharmaceuticals and Lactiga Collaboration
Kenox Pharmaceuticals Inc. is thrilled to announce a significant collaboration with Lactiga US, Inc. Together, they are embarking on a mission to develop pioneering mucosal-targeted therapies focusing on Secretory IgA (sIgA) for patients with compromised immune systems. This partnership comes with the backing of an important multi-million-dollar grant from the National Institute of Allergy and Infectious Diseases (NIAID), which is a component of the National Institutes of Health (NIH).
This unique collaboration harnesses Kenox Pharmaceuticals' robust expertise in the fields of nasal and inhaled pharmaceutical product development and manufacturing. Their joint endeavor aims to expedite the preclinical stages of developing innovative therapies that aim to bolster mucosal immunity in individuals facing immunodeficiencies.
The financial support from the grant will enhance Lactiga's platform technology focused on sIgA and extend Kenox's capabilities in biologic delivery systems through inhaled and intranasal methods.
Sitaram Velaga, President and CEO of Kenox, expressed his enthusiasm: "We are heavily invested in this partnership with Lactiga, and the grant from NIH reflects the great promise our joint venture holds in developing potentially transformative treatments for individuals with immunodeficiencies. This collaboration is essential to meet the significant needs within the healthcare landscape."
Rikin Mehta, CEO and Co-founder of Lactiga, added, "For years, immunologists have been on the lookout for an effective nasal sIgA spray to prevent recurrent respiratory infections in vulnerable individuals. This partnership is paving the way for a groundbreaking intranasal sIgA therapy, addressing a critical healthcare need, and representing a first in the field."
Significantly, this collaboration epitomizes an essential stride forward in nasal immunotherapy, with the potential to positively impact the lives of individuals grappling with immunodeficiency issues.
About Kenox Pharmaceuticals Inc.
Founded in 2018 and located in the greater area of New Jersey, Kenox Pharmaceuticals specializes in the development of pharmaceutical aerosol products. Their offerings include a range of delivery devices such as soft mist inhalers (SMIs), pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs), nebulizers, nasal sprays, and more. Whether the products involve small molecules or biologics, Kenox ensures compliance with various compendial monographs while offering unparalleled expertise in formulation design, compounding, and testing.
About Lactiga US, Inc.
Lactiga is an innovative biotechnology firm that is focused on developing novel mucosal antibodies that are derived from human breast milk. Their aim is to enhance the quality of life for vulnerable populations, particularly those with compromised health. With an emphasis on secretory IgA (sIgA)-based therapeutics, Lactiga utilizes their proprietary technologies to create targeted therapeutic solutions for infectious and inflammatory conditions.
Why This Collaboration Matters
The collaboration between Kenox and Lactiga represents a critical advancement in the development of therapies that address significant unmet medical needs. With both companies providing their core competencies, the joint effort is likely to produce therapies that could revolutionize the treatment of immunodeficiency. This initiative highlights the value of collaboration in healthcare, as bringing complementary strengths together can lead to significant breakthroughs.
The Future of Mucosal Immunotherapy
As the world continues to grapple with various health challenges, the focus on innovative therapeutic approaches becomes ever more crucial. The partnership between Kenox Pharmaceuticals Inc. and Lactiga US, Inc. showcases a unified commitment to improving healthcare outcomes through cutting-edge research in immunotherapy. As they work together to explore the potential of sIgA therapies, the industry watches with anticipation for advancements that could change the landscape for patients who suffer from immune deficiencies.
Frequently Asked Questions
What is the focus of the collaboration between Kenox and Lactiga?
The collaboration aims to develop novel mucosal-targeted therapies focusing on Secretory IgA for patients with compromised immune systems.
What support is Lactiga receiving for its technology?
Lactiga is supported by a significant multi-million-dollar STTR grant from the National Institute of Allergy and Infectious Diseases.
What areas of expertise does Kenox bring to this collaboration?
Kenox Pharmaceuticals offers extensive knowledge in nasal and inhaled pharmaceutical development and manufacturing.
Why are sIgA therapies significant?
sIgA therapies can potentially reduce recurrent respiratory infections in immunodeficient individuals, addressing critical healthcare needs.
What is the future outlook for this partnership?
The collaboration holds the promise of advancing innovative treatments that could significantly improve the lives of individuals with immunodeficiencies.
